Caplacizumab is a nano-antibody drug, mainly used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It blocks the interaction between von Willebrand factor (vWF) and platelets, reduces platelet consumption, and thus improves patient prognosis.
Instructions for Caplacizumab
Caplacizumab is a lyophilized powder injection, each bottle contains 11mg of the main ingredient Caplacizumab. Its use must strictly follow the recommended dose and administration method to clarify efficacy and safety.
Basic information of the drug
Caplacizumab is produced by Sanofi in France, with the trade name CABLIVI, and the specification is 11 mg/bottle. The drug needs to be refrigerated and has a shelf life of 24 months. Currently, the drug has not been marketed in China, and there are no generic drugs.
Usage and Dosage
Caplacizumab needs to be injected intravenously before plasma exchange, and then 11 mg is injected subcutaneously every day. The treatment cycle is usually 30 days, which can be extended to 28 days depending on the condition. The missed dose must be taken within 12 hours, and the missed dose should be skipped. The drug should be stopped 7 days before surgery to avoid bleeding risks.
The use of Caplacizumab must strictly follow the doctor's instructions. Its special administration method and storage conditions provide important guarantees for treatment.
The role of Caplacizumab
Caplacizumab provides a new treatment option for aTTP patients through its unique mechanism of action.
Mechanism of action
Caplacizumab specifically blocks the binding of vWF to platelets, reducing platelet adhesion and consumption. This mechanism effectively inhibits the formation of microthrombi, thereby improving the symptoms of aTTP patients.
Clinical effect
Combined with plasma exchange and immunosuppressive therapy, Caplacizumab can significantly shorten the platelet recovery time and reduce the recurrence rate. Clinical data show that it can reduce the number of plasma exchange days and plasma usage, and improve the quality of life of patients.
The role of Caplacizumab is not only reflected in the rapid relief of symptoms, but also in its stability and safety in long-term treatment.
Efficacy of Caplacizumab
Caplacizumab has shown multiple efficacy in the treatment of aTTP, bringing significant benefits to patients.
Therapeutic advantages
Caplacizumab can quickly control the disease and reduce the risk of organ damage. Its nano-antibody characteristics give it high affinity and specificity, and its efficacy is better than traditional treatment.
Safety evaluation
Common adverse reactions include nose bleeding, headache and gingival bleeding, with an incidence of about 15%. Severe side effects such as bone marrow suppression or allergic reactions require immediate discontinuation of the drug. Special populations such as pregnant women and those with liver damage should use it with caution.
The efficacy of Caplacizumab is not only reflected in its efficacy, but its safety also provides the possibility of long-term treatment, bringing new hope to patients with aTTP.
